Send to

Choose Destination
See comment in PubMed Commons below
J Immunol Methods. 2014 Jul;409:62-71. doi: 10.1016/j.jim.2014.04.011. Epub 2014 May 4.

Development and implementation of a proficiency testing program for Luminex bead-based cytokine assays.

Author information

  • 1Duke Human Vaccine Institute, Department of Medicine, Duke University Medical Center, Durham, NC 27710, United States.
  • 2Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, United States.
  • 3Department of Pathology and Laboratory Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, United States; Cancer Immunotherapy Consortium of the Cancer Research Institute, United States.
  • 4Duke Human Vaccine Institute, Department of Medicine, Duke University Medical Center, Durham, NC 27710, United States. Electronic address:


Luminex bead array assays are widely used for rapid biomarker quantification due to the ability to measure up to 100 unique analytes in a single well of a 96-well plate. There has been, however, no comprehensive analysis of variables impacting assay performance, nor development of a standardized proficiency testing program for laboratories performing these assays. To meet this need, the NIH/NIAID and the Cancer Immunotherapy Consortium of the Cancer Research Institute collaborated to develop and implement a Luminex assay proficiency testing program as part of the NIH/NIAID-sponsored External Quality Assurance Program Oversight Laboratory (EQAPOL) at Duke University. The program currently monitors 25 domestic and international sites with two external proficiency panels per year. Each panel includes a de-identified commercial Luminex assay kit with standards to quantify human IFNγ, TNFα, IL-6, IL-10 and IL-2, and a series of recombinant cytokine-spiked human serum samples. All aspects of panel development, testing and shipping are performed under GCLP by EQAPOL support teams. Following development testing, a comprehensive site proficiency scoring system comprised of timeliness, protocol adherence, accuracy and precision was implemented. The overall mean proficiency score across three rounds of testing has remained stable (EP3: 76%, EP4: 75%, EP5: 77%); however, a more detailed analysis of site reported results indicates a significant improvement of intra- (within) and inter- (between) site variation, suggesting that training and remediation for poor performing sites may be having a positive impact on proficiency. Through continued proficiency testing, identification of variables affecting Luminex assay outcomes will strengthen efforts to bring standardization to the field.

Copyright © 2014 Elsevier B.V. All rights reserved.


Cytokines; GCLP; Luminex; Multiplex; Proficiency

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk